[Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis].

Abstract

BACKGROUND:

To assess the long term safety and therapeutic action of lornoxicam, a new non steroidal anti-inflammatory agent, in rheumatoid arthritis.

METHODS:

Open trial was carried out on different dosage schedules of lornoxicam (4 or 8 mg bid and 4mg tid) administered for six to twelve months. Patients of both sexes were enrolled, with classical or definite rheumatoid arthritis according to the A.R.A. criteria.

RESULTS:

Thirty-four patients (28 F, 6 M) were admitted, mean age (+/- SD) 53.9+/-14.2 years, mean duration of illness 9.2+/-10.7 years. Lornoxicam 8-16 mg/day showed good safety and therapeutic activity in long term treatment. Clinical improvement was limited, but progression of the disease was controlled. No adverse events were complained.

CONCLUSIONS:

Lornoxicam presented a worth-while therapeutic action and a good tolerability in rheumatoid arthritis long term treatment.

• Authors: L Frizziero, M C Focherini, M Valentini, M Reta, P Rocchi
• Journal: Minerva medica (Minerva Med) Vol. 93 Issue 4 Pg. 315-20 (Aug 2002) ISSN: 0026-4806 [Print] Italy
• Vernacular Title: Studio a lungo termine su efficacia e sicurezza terapeutica di lornoxicam nell'artrite reumatoide.
• PMID: 12207202 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Piroxicam
• lornoxicam

Topics

• Adult
• Aged
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Piroxicam (analogs & derivatives, therapeutic use)
• Time Factors